Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Venous Thrombosis

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 19 articles:
HTML format



Single Articles


    November 2023
  1. GOTO S, Goto S
    Clinical Course of Isolated Distal Venous Thromboembolism in Patients With Active Cancer in a Nation With an Overall Low Risk of Thrombosis.
    Circulation. 2023;148:1677-1679.
    PubMed    


  2. HOSOKAWA K, Watanabe H, Taniguchi Y, Ikeda N, et al
    A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067528.
    PubMed    


    March 2023
  3. LASSEN MCH, Modin D, Skaarup KG, Johansen ND, et al
    Risk of Incident Thromboembolic and Ischemic Events After COVID-19 Vaccination Compared With SARS-CoV-2 Infection.
    Circulation. 2023;147:843-845.
    PubMed    


    January 2023
  4. GOLDBERG JB, Giri J, Kobayashi T, Ruel M, et al
    Surgical Management and Mechanical Circulatory Support in High-Risk Pulmonary Embolisms: Historical Context, Current Status, and Future Directions: A Scientific Statement From the American Heart Association.
    Circulation. 2023 Jan 23. doi: 10.1161/CIR.0000000000001117.
    PubMed     Abstract available


    September 2022
  5. THIBORD F, Klarin D, Brody JA, Chen MH, et al
    Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors.
    Circulation. 2022 Sep 26:101161CIRCULATIONAHA122059675.
    PubMed     Abstract available


    June 2022
  6. POGOSOVA N, Bosch J, Bhatt DL, Fox KAA, et al
    Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis.
    Circulation. 2022;145:1875-1877.
    PubMed    


    April 2022
  7. PARK DW, Ahn JM, Kang DY, Kim KW, et al
    Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial.
    Circulation. 2022 Apr 4. doi: 10.1161/CIRCULATIONAHA.122.059512.
    PubMed     Abstract available


    March 2022
  8. STEVENS H, Canovas R, Tran H, Peter K, et al
    Inherited Thrombophilias Are Associated With a Higher Risk of COVID-19-Associated Venous Thromboembolism: A Prospective Population-Based Cohort Study.
    Circulation. 2022;145:940-942.
    PubMed    


    November 2021
  9. NAEIJE R
    Letter by Naeije Regarding Article, "Oxygen Pathway Limitations in Patients With Chronic Thromboembolic Pulmonary Hypertension".
    Circulation. 2021;144:e328-e329.
    PubMed    


  10. HOWDEN EJ, Ruiz-Carmona S, La Gerche A, Delcroix M, et al
    Response by Howden et al to Letter Regarding Article, "Oxygen Pathway Limitations in Patients With Chronic Thromboembolic Pulmonary Hypertension".
    Circulation. 2021;144:e330-e331.
    PubMed    


    August 2021
  11. AN ZY, Peng D, Shi YJ
    A Patient With Acute Shortness of Breath and Inferior ST-Segment Elevation: A Diagnostic Trap.
    Circulation. 2021;144:577-579.
    PubMed    


    May 2021
  12. ROBERT-EBADI H, Robin P, Hugli O, Verschuren F, et al
    Impact of the Age-Adjusted D-Dimer Cutoff to Exclude Pulmonary Embolism: A Multinational Prospective Real-Life Study (the RELAX-PE Study).
    Circulation. 2021;143:1828-1830.
    PubMed    


    April 2021
  13. HOWDEN EJ, Ruiz-Carmona S, Claeys M, de Bosscher R, et al
    Oxygen Pathway Limitations in Patients with Chronic Thromboembolic Pulmonary Hypertension.
    Circulation. 2021 Apr 15. doi: 10.1161/CIRCULATIONAHA.120.052899.
    PubMed     Abstract available


    March 2021
  14. BUKHARI S, Barakat AF, Eisele YS, Nieves R, et al
    Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Circulation. 2021;143:1335-1337.
    PubMed    


    February 2021

  15. Correction to: Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association.
    Circulation. 2021;143:e249.
    PubMed    


    November 2020
  16. PACKARD CJ
    Letter by Packard Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Tr
    Circulation. 2020;142:e333-e334.
    PubMed    


  17. SCHWARTZ GG, Szarek M, Bittner VA, Steg PG, et al
    Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Ran
    Circulation. 2020;142:e335-e336.
    PubMed    


    October 2020
  18. MARSTON NA, Ruff CT, Sabatine MS
    Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism".
    Circulation. 2020;142:e264.
    PubMed    


  19. QI Z, Sun A, Ge J
    Letter by Qi et al Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism".
    Circulation. 2020;142:e262-e263.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Venous Thrombosis is free of charge.